Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects

Am J Hypertens. 2007 Jan;20(1):1-5. doi: 10.1016/j.amjhyper.2006.06.005.


Background: About one in four adults suffer from prehypertension. People with prehypertension are at risk of developing hypertension, being a biomarker for cardiovascular disease risk. The use of milk-derived protein hydrolysates containing peptides with angiotensin-converting enzyme (ACE) inhibiting properties may reduce blood pressure (BP) and thus the risk of developing hypertension.

Methods: We investigated the BP-lowering effect of a casein-derived protein hydrolysate (C12 Peptide) during a 4-week intervention period in prehypertensive subjects. After a 2-week run-in period, 48 Taiwanese volunteers were randomly assigned to either placebo or C12 Peptide tablets for 4 weeks, followed by a 2-week off-treatment period. After the run-in period, BP was measured weekly.

Results: Baseline values for systolic BP (mean +/- SEM) in the placebo and C12 Peptide groups were 137.1 +/- 3.1 and 137.9 +/- 2.4 mm Hg, respectively; those for diastolic BP were 85.2 +/- 2.1 and 86.9 +/- 2.0 mm Hg, respectively. Four weeks repeated daily intake of 3.8 g C12 Peptide reduced significantly systolic and diastolic BP by 10.7 +/- 1.6 mm Hg and 6.9 +/- 1.2 mm Hg, respectively, compared to baseline. Furthermore, plasma angiotensin II and aldosterone levels were reduced significantly (P < .05). The placebo group showed a BP reduction of 3.6 +/- 2.4 and 2.7 +/- 1.6 mm Hg in systolic and diastolic BP, respectively (P = not significant). No evidence of side effects was observed.

Conclusions: This study shows that C12 Peptide reduces BP in prehypertensive people.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone / blood
  • Angiotensin II / blood
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Animals
  • Blood Pressure / drug effects*
  • Caseins / adverse effects
  • Caseins / therapeutic use
  • Cattle
  • Double-Blind Method
  • Female
  • Humans
  • Hypertension / prevention & control*
  • Male
  • Middle Aged


  • Angiotensin-Converting Enzyme Inhibitors
  • Caseins
  • Angiotensin II
  • Aldosterone
  • casein hydrolysate